IGF1R Protein: The Core Receptor of the Insulin-like Growth Factor Signaling Axis and a Key Molecule for Tumor-Targeted Therapy

Author: Senior Product Manager of UA Views：9

This article focuses on the molecular characteristics and biological functions of insulin-like growth factor 1 receptor (IGF1R/CD221), systematically elaborating its structural composition and ligand activation mechanism as a tetrameric transmembrane receptor tyrosine kinase, analyzing the signaling network through which IGF1R regulates cell proliferation, survival, metastasis, and angiogenesis via the PI3K-AKT and RAS-RAF-MEK-ERK pathways, and exploring the overexpression of IGF1R in various malignant tumors and its association with resistance to antitumor drugs.

Recent Advances
Product Information

Recent Advances

IGF1R Protein: The Core Receptor of the Insulin-like Growth Factor Signaling Axis and a Key Molecule in Tumor-Targeted Therapy

Brief Introduction: This article focuses on the molecular characteristics and biological functions of the insulin-like growth factor 1 receptor (IGF1R/CD221), systematically elaborating on its structural composition as a tetrameric transmembrane receptor tyrosine kinase and its ligand activation mechanism, analyzing the signaling network through which IGF1R regulates cell proliferation, survival, metastasis, and angiogenesis via the PI3K-AKT and RAS-RAF-MEK-ERK pathways, and discussing the overexpression of IGF1R in various malignant tumors and its association with resistance to anti-tumor drugs.

I. Molecular Structure and Receptor Composition of IGF1R.

IGF1R, namely the insulin-like growth factor 1 receptor, also known as CD221, is a tetrameric transmembrane receptor tyrosine kinase widely expressed in normal human tissues and upregulated in various cancers, including colorectal cancer, non-small cell lung cancer, ovarian cancer, and childhood cancers. The receptor consists of two α and two β subunits connected by disulfide bonds, forming a disulfide-linked α₂β₂ heterotetrameric structure. The extracellular α subunit is responsible for ligand binding, while the β subunit includes a transmembrane domain and a cytoplasmic tyrosine kinase domain. IGF1R shares significant structural homology with the insulin receptor and can form functionally active hybrid receptors. This structural homology not only explains the cross-regulation between IGF1R and the insulin signaling system but also presents structural challenges for the development of highly selective IGF1R-targeted drugs.

II. Ligand Activation and Signal Transduction Mechanism of IGF1R.

Ligand binding activates the tyrosine kinase activity of IGF1R, leading to trans-subunit autophosphorylation and stimulating cascade signal activation, including the PI3K-mTOR and MAPK pathways. Specifically, IGF-1 or IGF-2 ligands bind to the cysteine-rich extracellular α chain, inducing conformational changes that trigger reverse autophosphorylation of the intracellular β subunit, activating the PI3K/AKT and RAS/RAF/MEK/ERK signaling pathways, coordinating cell proliferation, survival, anti-apoptotic responses, and metabolic adaptation. The synergistic activation of these two core pathways makes IGF1R a key hub connecting growth factor signaling with cellular metabolic reprogramming.

III. Biological Functions and Oncogenic Effects of IGF1R.

It has been reported that activation of IGF1R can stimulate cell proliferation, survival, transformation, metastasis, and angiogenesis, while inhibition of IGF1R has been shown to suppress tumorigenesis in several human xenograft models. Meanwhile, IGF1R signaling activation is also associated with resistance to various anti-tumor inhibitors, including EGFR inhibitors. This resistance association has important clinical significance——during EGFR inhibitor treatment, compensatory activation of the IGF1R signaling pathway may become an important mechanism for tumor cells to evade drug killing, making combined blockade of the IGF1R and EGFR signaling axes an important strategic direction for overcoming resistance.

IV. Expression and Clinical Significance of IGF1R in Malignant Tumors.

Clinically, overexpression or genomic amplification of IGF1R has been found in various human malignant tumors, especially non-small cell lung cancer, breast cancer, and Ewing sarcoma, with IGF1R serving as an independent prognostic indicator and a druggable therapeutic target. The high expression of IGF1R in Ewing sarcoma is particularly noteworthy, as the tumor's high dependence on IGF1R signaling makes it a classic model for studying IGF1R-targeted therapy. In non-small cell lung cancer and breast cancer, IGF1R overexpression is associated with tumor aggressiveness, treatment resistance, and poor prognosis, suggesting that it is not only a therapeutic target but also a molecular marker for prognostic assessment.

V. Conclusion.

In IGF1R-related basic research and drug development, high-quality recombinant IGF1R protein is a core tool for dissecting its binding mechanism with ligands IGF-1/IGF-2 and evaluating targeted drug activity. Fc-chimeric IGF1R protein forms dimers through the Fc fragment, more closely resembling the dimerization conformation of the natural receptor on the cell surface, and can be used for high-affinity ligand binding analysis and antibody screening. To meet the needs of IGF1R functional research and tumor-targeted drug screening, U-Protein offers CD221/IGF1R Fc Chimera Protein, Human. This product is suitable for applications including binding activity analysis of IGF1R with IGF-1/IGF-2 ligands, in vitro screening and evaluation of IGF1R-targeted monoclonal antibodies and combination therapeutic drugs, mechanistic studies of IGF1R-mediated PI3K-AKT and MAPK signaling pathways, and IGF1R functional research in tumor models such as non-small cell lung cancer, breast cancer, and Ewing sarcoma.

As the core receptor of the insulin-like growth factor signaling axis, IGF1R, with its disulfide-linked α₂β₂ heterotetrameric structure, ligand-induced trans-autophosphorylation activation mechanism, and multiple functions in regulating cell proliferation, survival, metastasis, and angiogenesis through the PI3K-AKT and RAS-RAF-MEK-ERK pathways, has become a highly promising therapeutic target for various malignant tumors including non-small cell lung cancer, breast cancer, and Ewing sarcoma. From the structural homology between IGF1R and the insulin receptor to its clinical association with EGFR inhibitor resistance, from monoclonal antibody monotherapy development to combination therapeutic strategies with EGFR inhibitors and immune checkpoint blockade, IGF1R continues to drive the in-depth development of the tumor-targeted therapy field. CD221/IGF1R Fc Chimera Protein, Human provides reliable tool support for mechanistic research of the IGF1R signaling network and targeted drug development, and will continue to facilitate innovative exploration in the field of precision cancer therapy.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next